Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) delivers innovative therapeutic ultrasound solutions for urological care through its HIFU and lithotripsy technologies. This news hub provides investors and medical professionals with essential updates on the company's advancements in robotic medical devices, regulatory milestones, and global market strategies.
Access real-time announcements including clinical trial results, product approvals, financial disclosures, and strategic partnerships. Our curated collection features press releases about EDAP's three operational divisions: HIFU tumor ablation systems, ESWL stone treatment devices, and distribution of complementary medical technologies.
Stay informed about developments in minimally-invasive treatment solutions that demonstrate EDAP's commitment to advancing urological care. The resource is regularly updated with material events affecting the company's position in the competitive medical devices sector.
Bookmark this page for streamlined access to verified information about EDAP's technological innovations, international expansion efforts, and research collaborations with leading medical institutions.
EDAP TMS SA (Nasdaq: EDAP) announced it will showcase its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform for prostate cancer management at the Annual Meeting of the American Urological Association (AUA), scheduled for April 28-May 1 in Chicago, IL. This year, EDAP will have its largest presence at the AUA, featuring Focal Therapy discussions and hands-on demonstrations. Key urologists will present the advantages of HIFU therapy, emphasizing its efficacy in meeting oncological standards while preserving patient quality of life. The AUA meeting highlights the ongoing clinical acceptance and adoption of EDAP's technology among physicians worldwide.